Advisory

Consumption of Isoniazid Syrup for TB Preventive Therapy

Isoniazid monotherapy for six (6) months is one of the treatment options for Latent TB Infection (LTBI) in both adults and children in countries with high and low TB incidence as recommended by the World Health Organization (WHO). Furthermore, TB Preventive Therapy is an intervention in the management of (LTBI) for populations with the highest risk of progression to TB disease.

The Department of Health through the Disease Prevention Control Bureau - National Tuberculosis Control Program has procured Isoniazid syrup 200mg/5mL for 2019 with its aim to continuously increase TB Preventive Therapy (TPT) coverage. Due to the challenges in the delivery caused by the Enhanced Community Quarantine, distribution of Isoniazid syrup to respective Centers for Health Development just started from 3rd week of April until 1st week of May 2020. As you may be aware, dosage formulation in syrup has shorter shelf-life. Thus, please ensure that treatment has been initiated on or before **01 October 2020, as it will expire on 30 April 2021.**

Thank you for your cooperation.

[Signature]

MYRNA C. CABOTAJE, MD, MPH, CESO III
Undersecretary of Health
Public Health Services Team